妇产科指南

订阅

MedSci主页 / 所有栏目 / 妇产科指南

昆士兰临床指南：产前糖皮质激素的应用

2021-08-10 昆士兰卫生组织 昆士兰官网

糖皮质激素

本文件是昆士兰临床指南 (QCG) 产前皮质类固醇的补充。它提供了有关指南制定的补充信息，进行总结

中文标题：

昆士兰临床指南：产前糖皮质激素的应用

发布机构：

昆士兰卫生组织

发布日期：

2021-08-10

简要介绍：

本文件是昆士兰临床指南 (QCG) 产前皮质类固醇的补充。它提供了有关指南制定的补充信息，进行总结
建议，建议措施以协助实施和质量活动，以及总结了自原始出版以来指南的变化。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 昆士兰临床指南：产前糖皮质激素的应用.pdf)] GetToolGuiderByIdResponse(projectId=1, id=addcd1c0021809d2, title=昆士兰临床指南：产前糖皮质激素的应用, enTitle=, guiderFrom=昆士兰官网, authorId=0, author=, summary=本文件是昆士兰临床指南 (QCG) 产前皮质类固醇的补充。它提供了有关指南制定的补充信息，进行总结, cover=https://img.medsci.cn/202197/1631026069071_2020535.jpg, journalId=0, articlesId=null, associationId=264, associationName=昆士兰卫生组织, associationIntro=null, copyright=0, guiderPublishedTime=Tue Aug 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>本文件是昆士兰临床指南 (QCG) 产前皮质类固醇的补充。它提供了有关指南制定的补充信息，进行总结<br />建议，建议措施以协助实施和质量活动，以及总结了自原始出版以来指南的变化。</p>, tagList=[TagDto(tagId=541, tagName=糖皮质激素)], categoryList=[CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=541, guiderKeyword=糖皮质激素, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3012, appHits=114, showAppHits=0, pcHits=397, showPcHits=2897, likes=1, shares=15, comments=12, approvalStatus=1, publishedTime=Tue Sep 07 23:10:53 CST 2021, publishedTimeString=2021-08-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Sep 07 22:48:00 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 18:27:10 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 昆士兰临床指南：产前糖皮质激素的应用.pdf)])
2021 昆士兰临床指南：产前糖皮质激素的应用.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1201215, encodeId=963112012153c, content=现在才看到！感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c255446462, createdName=ms2000001317731432, createdTime=Thu Mar 10 11:37:34 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188752, encodeId=c7131188e52fc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c70d5596086, createdName=ms9000001414426655, createdTime=Fri Jan 28 08:27:17 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066390, encodeId=06f41066390a6, content=受益匪浅！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Nov 02 22:11:04 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052058, encodeId=609b105205896, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/z4Az5l1QkBBEtKDRRseztsZpUicScsicF8jMvJW3tch8ibiaVTGDRWJByv1vFGQ4Pzxu7liaBPYXENY6DbD8AfRK60Q/0, createdBy=73c02203188, createdName=石虎谭, createdTime=Thu Sep 16 18:57:17 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016816, encodeId=154310168162e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6d75603085, createdName=ms4000000450890211, createdTime=Sun Sep 12 16:27:26 CST 2021, time=2021-09-12, status=1, ipAttribution=)]
    2022-03-10 ms2000001317731432

    现在才看到！感谢！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1201215, encodeId=963112012153c, content=现在才看到！感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c255446462, createdName=ms2000001317731432, createdTime=Thu Mar 10 11:37:34 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188752, encodeId=c7131188e52fc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c70d5596086, createdName=ms9000001414426655, createdTime=Fri Jan 28 08:27:17 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066390, encodeId=06f41066390a6, content=受益匪浅！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Nov 02 22:11:04 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052058, encodeId=609b105205896, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/z4Az5l1QkBBEtKDRRseztsZpUicScsicF8jMvJW3tch8ibiaVTGDRWJByv1vFGQ4Pzxu7liaBPYXENY6DbD8AfRK60Q/0, createdBy=73c02203188, createdName=石虎谭, createdTime=Thu Sep 16 18:57:17 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016816, encodeId=154310168162e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6d75603085, createdName=ms4000000450890211, createdTime=Sun Sep 12 16:27:26 CST 2021, time=2021-09-12, status=1, ipAttribution=)]
    2022-01-28 ms9000001414426655

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1201215, encodeId=963112012153c, content=现在才看到！感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c255446462, createdName=ms2000001317731432, createdTime=Thu Mar 10 11:37:34 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188752, encodeId=c7131188e52fc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c70d5596086, createdName=ms9000001414426655, createdTime=Fri Jan 28 08:27:17 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066390, encodeId=06f41066390a6, content=受益匪浅！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Nov 02 22:11:04 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052058, encodeId=609b105205896, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/z4Az5l1QkBBEtKDRRseztsZpUicScsicF8jMvJW3tch8ibiaVTGDRWJByv1vFGQ4Pzxu7liaBPYXENY6DbD8AfRK60Q/0, createdBy=73c02203188, createdName=石虎谭, createdTime=Thu Sep 16 18:57:17 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016816, encodeId=154310168162e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6d75603085, createdName=ms4000000450890211, createdTime=Sun Sep 12 16:27:26 CST 2021, time=2021-09-12, status=1, ipAttribution=)]
    2021-11-02 ms3000001592172450

    受益匪浅！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1201215, encodeId=963112012153c, content=现在才看到！感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c255446462, createdName=ms2000001317731432, createdTime=Thu Mar 10 11:37:34 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188752, encodeId=c7131188e52fc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c70d5596086, createdName=ms9000001414426655, createdTime=Fri Jan 28 08:27:17 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066390, encodeId=06f41066390a6, content=受益匪浅！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Nov 02 22:11:04 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052058, encodeId=609b105205896, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/z4Az5l1QkBBEtKDRRseztsZpUicScsicF8jMvJW3tch8ibiaVTGDRWJByv1vFGQ4Pzxu7liaBPYXENY6DbD8AfRK60Q/0, createdBy=73c02203188, createdName=石虎谭, createdTime=Thu Sep 16 18:57:17 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016816, encodeId=154310168162e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6d75603085, createdName=ms4000000450890211, createdTime=Sun Sep 12 16:27:26 CST 2021, time=2021-09-12, status=1, ipAttribution=)]
    2021-09-16 石虎谭

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1201215, encodeId=963112012153c, content=现在才看到！感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c255446462, createdName=ms2000001317731432, createdTime=Thu Mar 10 11:37:34 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188752, encodeId=c7131188e52fc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c70d5596086, createdName=ms9000001414426655, createdTime=Fri Jan 28 08:27:17 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066390, encodeId=06f41066390a6, content=受益匪浅！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Nov 02 22:11:04 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052058, encodeId=609b105205896, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/z4Az5l1QkBBEtKDRRseztsZpUicScsicF8jMvJW3tch8ibiaVTGDRWJByv1vFGQ4Pzxu7liaBPYXENY6DbD8AfRK60Q/0, createdBy=73c02203188, createdName=石虎谭, createdTime=Thu Sep 16 18:57:17 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016816, encodeId=154310168162e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6d75603085, createdName=ms4000000450890211, createdTime=Sun Sep 12 16:27:26 CST 2021, time=2021-09-12, status=1, ipAttribution=)]
    2021-09-12 ms4000000450890211

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

围手术期糖皮质激素医-药专家共识

广东省药学会 · 2021-06-21

2020 AA/RCP/SE指南：肾上腺功能不全患者围术期糖皮质激素管理

麻醉医师协会（英国）(AA,Association of Anaesthetists) · 2020-02-03

糖皮质激素在儿童风湿病中应用专家共识（下）

中华医学会儿科学分会免疫学组 · 2019-01-31

糖皮质激素在儿童风湿病中应用专家共识（上）

中华医学会儿科学分会 · 2018-03-08

《2017 年ACR 糖皮质激素性骨质疏松症防治指南》解读·

暂未更新 · 2018-01-20

2017 临床实践指南：应用糖皮质激素治疗咽喉痛

国外耳鼻喉相关专家组（统称） · 2017-09-20

拓展阅读

2010 ACR 糖皮质激素相关骨质疏松防治指南

美国风湿病学会(ACR,American College of Rheumatology) · 2010-11-01

2011 糖皮质激素雾化吸入疗法在儿科应用的专家共识

中国儿科相关医学专家组（统称） · 2011-01-01

2011 糖皮质激素类药物临床应用指导原则

中华医学会(CMA,Chinese Medical Association) · 2011-02-15

肾上腺糖皮质激素在围术期应用的专家共识

中华医学会麻醉学分会 · 2012-12-20

2013 糖皮质激素诱导的骨质疏松诊治的专家共识

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2013-06-01

2013 EULAR循证建议：中等至大剂量糖皮质激素疗法治疗风湿性疾病

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2013-07-19